Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

The Original Article was published on 20 May 2021

Correction to: Leukemia

https://doi.org/10.1038/s41375-021-01261-x

Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Francisco Cervantes.

Additional information

The original article can be found online at https://doi.org/10.1038/s41375-021-01261-x.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cervantes, F., Ross, D.M., Radinoff, A. et al. Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia (2021). https://doi.org/10.1038/s41375-021-01396-x

Download citation

Search

Quick links